Ethyl-eicosapentaenoate modulates changes in neurochemistry and brain lipids induced by parkinsonian neurotoxin 1-methyl-4-phenylpyridinium in mouse brain slices

European Journal of Pharmacology

Volumn 649, Issue 1-3, 2010, Pages 127-134

  Meng, QingJia ^a   Luchtman, Dirk W ^a,b   El Bahh, Bouchaib ^a   Zidichouski, Jeffrey A ^a   Yang, Jun ^a,c   Song, Cai ^a  

^a UNIVERSITY OF PRINCE EDWARD ISLAND   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Jiangsu Provincial Institute for Novel Pharmaceuticals at Taizhou   (China)

Author keywords

1 Methyl 4 phenyl 1,2,3,6, tetrahydropyridine; Inflammation; Neurochemistry; Omega 3; Omega 6; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ARACHIDONIC ACID; CASPASE 3; CYCLOOXYGENASE 2; DOCOSAPENTAENOIC ACID; DOPAMINE; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; LINOLEIC ACID; MESSENGER RNA; NEUROTRANSMITTER; NORADRENALIN; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PHOSPHOLIPASE A2; POLYUNSATURATED FATTY ACID; PROTEIN BAX; PROTEIN BCL 2;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN SLICE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE MARKER; FATTY ACID ANALYSIS; FRONTAL CORTEX; GENE EXPRESSION; LIPID BRAIN LEVEL; LIPID COMPOSITION; MALE; MOUSE; NEUROCHEMISTRY; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; APOPTOSIS REGULATORY PROTEINS; BRAIN; BRAIN CHEMISTRY; CORPUS STRIATUM; CYCLOOXYGENASE 2; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FRONTAL LOBE; INFLAMMATION MEDIATORS; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; PARKINSON DISEASE, SECONDARY; PHOSPHOLIPASES A2, CYTOSOLIC; RNA, MESSENGER;

EID: 78049245397     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.09.046     Document Type: Article

References (40)

1. + toxicity in rat striatal slices: relationship between non-selective effects and free radical production. Neurochem. Res. 1996, 21:73-78.
2. Bernardo A., Minghetti L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr. Pharm. 2006, 12:93-109.
3. Bousquet M., Saint-Pierre M., Julien C., Salem N., Cicchetti F., Calon F. Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. FASEB 2008, 22:1213-1225.
4. Bousquet M., Gibrat C., Saint-Pierre M., Julien C., Calon F., Cicchetti F. Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:1401-1408.
5. Bywood P.T., Johnson S.M. Mitochondrial complex inhibitors preferentially damage substantia nigra dopamine neurons in rat brain slices. Exp. Neurol. 2003, 179:47-59.
6. Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot. Essent. Fatty Acids 2006, 75:259-269.
7. Chalon S., Delion-Vancassel S., Belzung C., Guilloteau D., Leguisquet A.M., Besnard J.C., Durand G. Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J. Nutr. 1998, 128:2512-2519.
8. Colgan S.M., Tang D., Werstuck G.H., Austin R.C. Endoplasmic reticulum stress causes the activation of sterol regulatory element binding protein-2. Int. J. Biochem. Cell Biol. 2007, 39:1843-1851.
9. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
10. Delattre A.M., Kiss A., Szawka R.E., Anselmo-Franci J.A., Bagatini P.B., Xavier L.L., Rigon P., Achaval M., Iagher F., de David C., Marroni N.A., Ferraz A.C. Evaluation of chronic omega-3 fatty acids supplementation on behavioral and neurochemical alterations in 6-hydroxydopamine-lesion model of Parkinson's disease. Neurosci. Res. 2010, 66:256-264.
11. Di Monte D.A. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?. Lancet Neurol. 2003, 2:531-538.
12. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957, 226:497-509.
13. Horrobin D.F. A new category of psychotropic drugs: neuroactive lipids as exemplified by ethyl eicosapentaenoate (E-E). Prog. Drug Res. 2002, 59:171-199.
14. Horrobin D.F., Jenkins K., Bennett C.M., Christie W.W. Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding. Prostaglandins Leukot. Essent. Fatty Acids 2002, 66:83-90.
15. Huo T.L., Healy D.P. Prostaglandin E2 production in rat IMCD cells. I. Stimulation by dopamine. Am. J. Physiol. 1991, 61:647-654.
16. Huot P., Lévesque M., Parent A. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Brain 2007, 130:222-232.
17. Jin J., Shie F.S., Liu J., Wang Y., Davis J., Schantz A.M., Montine K.S., Montine T.J., Zhang J. Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. J. Neuroinflammation 2007, 4:2.
18. Julien C., Berthiaume L., LHadj-Tahar A., Rajput A.H., Bédard P.J., Di Paolo T., Julien P., Calon F. Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochem. Int. 2006, 48:404-414.
19. Kawashima A., Harada T., Kami H., Yano T., Imada K., Mizuguchi K. Effects of eicosapentaenoic acid on synaptic plasticity, fatty acid profile and phosphoinositide 3-kinase signaling in rat hippocampus and differentiated PC12 cells. J. Nutr. Biochem. Epub 2009, 21:268-277.
20. Kitajka K., Puskás L.G., Zvara A., Hackler L., Barceló-Coblijn G., Yeo Y.K., Farkas T. The role of n-3 polyunsaturated fatty acids in brain: modulation of rat brain gene expression by dietary n-3 fatty acids. Proc. Natl. Acad. Sci. USA 2002, 99:2619-2624.
21. Lappas M., Rice G.E. Phospholipase A2 isozymes in pregnancy and parturition. Prostaglandins Leukot. Essent. Fatty Acids 2004, 70:87-100.
22. Luchtman D.W., Shao D., Song C. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol. Behav. 2009, 98:130-138.
23. Mickleborough T.D., Tecklenburg S.L., Montgomery G.S., Lindley M.R. Eicosapentaenoic acid is more effective than docosahexaenoic acid in inhibiting proinflammatory mediator production and transcription from LPS-induced human asthmatic alveolar macrophage cells. Clin. Nutr. 2009, 28:71-77.
24. Miyake Y., Sasaki S., Tanaka K., Fukushima W., Kiyohara C., Tsuboi Y., Yamada T., Oeda T., Miki T., Kawamura N., Sakae N., Fukuyama H., Hirota Y., Nagai M. Fukuoka Kinki Parkinson's Disease Study Group: dietary fat intake and risk of Parkinson's disease: a case-control study in Japan. J. Neurol. Sci. 2010, 288:117-122.
25. Pattarini R., Smeyne R.J., Morgan J.I. Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyrimidine model of Parkinson's disease. Neuroscience 2007, 145:654-668.
26. Peet M., Stokes C. Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs 2005, 65:1051-1059.
27. Pifl C., Hornykiewicz O., Giros B., Caron M.G. Catecholamine transporters and 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine neurotoxicity studies comparing the cloned human noradrenaline and human dopamine transporter. J. Pharmacol. Exp. Ther. 1996, 277:1437-1443.
28. Rabey J.M., Burns R.S. Neurochemistry. Parkinson's Disease: Diagnosis and Clinical Management 2002, 195-211. Demos Medical Publishing, New York, NY. W.J. Weiner, S.A. Factor (Eds.).
29. Rommelfanger K.S., Weinshenker D. Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem. Pharmacol. 2007, 74:177-190.
30. Rousselet E., Joubert C., Callebert J., Parain K., Tremblay L., Orieux G., Launay J.M., Cohen-Salmon C., Hirsch E.C. Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons or dose of parkinsonian toxin MPTP in mice. Neurobiol. Dis. 2003, 14:218-228.
31. Russo G.L. Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochem. Pharmacol. 2009, 77:937-946.
32. Sierra S., Lara-Villoslada F., Comalada M., Olivares M., Xaus J. Dietary eicosapentaenoic acid and docosahexaenoic acid equally incorporate as decosahexaenoic acid but differ in inflammatory effects. Nutrition 2008, 24:245-254.
33. Simopoulos A.P. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp. Biol. Med. (Maywood) 2008, 233:674-688.
34. +) on the efflux and metabolism of endogenous dopamine in rat striatal slices. J. Pharm. Pharmacol. 1988, 40:620-626.
35. Song C., Li X., Kang Z., Kadotomi Y. Omega-3 fatty acid ethyl-eicosapentaenoate attenuates IL-1beta-induced changes in dopamine and metabolites in the shell of the nucleus accumbens: involved with PLA2 activity and corticosterone secretion. Neuropsychopharmacology 2007, 32:736-744.
36. Song C., Manku M.S., Horrobin D.F. Long-chain polyunsaturated fatty acids modulate interleukin-1beta-induced changes in behavior, monoaminergic neurotransmitters, and brain inflammation in rats. J. Nutr. 2008, 138:954-963.
37. Vancassel S., Leman S., Hanonick L., Denis S., Roger J., Nollet M., Bodard S., Kousignian I., Belzung C., Chalon S. N-3 polyunsaturated fatty acid supplementation reverses stress-induced modifications on brain monoamine levels in mice. J. Lipid Res. 2007, 49:340-348.
38. Willis S., Samala R., Rosenberger T.A., Borges K. Eicosapentaenoic and docosahexaenoic acids are not anticonvulsant or neuroprotective in acute mouse seizure models. Epilepsia 2009, 50:138-142.
39. + cause decreases in dopamine content in mouse brain slices. Neurosci. Lett. 1990, 108:213-218.
40. Youdim K.A., Martin A., Joseph J.A. Essential fatty acids and the brain: possible health implications. Int. J. Dev. Neurosci. 2000, 18:383-399.